{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uaz:UAZ12701",
      "entity_text" : "SST0001",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:P35916",
      "entity_text" : "VEGFR3",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Currently, both VEGFR3 blocking antibodies (IMC-3C5) and heparanase inhibitors (SST0001, M402, PI-88, and PG545) are in various stages of clinical trial evaluation, and their efficacy with or without standard chemotherapy in large patient cohorts is yet to be determined (http://clinicaltrials.gov).",
  "reading_complete" : "2020-08-08T14:59:42Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T14:57:48Z",
  "trigger" : "blocking",
  "evidence" : [ "VEGFR3 blocking antibodies (IMC-3C5) and heparanase inhibitors (SST0001" ],
  "pmc_id" : "5098117",
  "score" : 0
}